These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24913809)

  • 1. Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.
    Matsumoto K; Mizuno R; Tanaka N; Ide H; Hasegawa M; Ishida M; Hayakawa N; Yasumizu Y; Hagiwara M; Hara S; Kikuchi E; Miyajima A; Nakagawa K; Nakajima Y; Nakamura S; Nakashima J; Oya M
    Med Oncol; 2014 Jul; 31(7):45. PubMed ID: 24913809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.
    Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Tanaka N; Takeda T; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
    World J Urol; 2020 Jul; 38(7):1749-1756. PubMed ID: 31559475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
    Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
    Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy.
    Saito T; Matsumoto K; Kosaka T; Yasumizu Y; Tanaka N; Takeda T; Morita S; Mizuno R; Asanuma H; Oya M
    Int J Clin Oncol; 2023 May; 28(5):707-715. PubMed ID: 36929093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.
    Taguchi S; Fukuhara H; Azuma T; Suzuki M; Fujimura T; Nakagawa T; Ishikawa A; Kume H; Igawa Y; Homma Y
    BMC Urol; 2014 Oct; 14():81. PubMed ID: 25323845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
    Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
    Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
    Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
    Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study.
    Fossati N; Robesti D; Karnes RJ; Soligo M; Boorjian SA; Bossi A; Coraggio G; Di Muzio N; Cozzarini C; Noris Chiorda B; Gandaglia G; Scarcella S; Bartkowiak D; Böhmer D; Shariat S; Goldner G; Battaglia A; Joniau S; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Wiegel T; Briganti A
    Eur Urol; 2019 Oct; 76(4):443-449. PubMed ID: 30799187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
    Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
    Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?
    Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
    Radiat Oncol; 2016 Jul; 11():102. PubMed ID: 27475986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.